Details

Autor(en) / Beteiligte

• Villa, Luisa L.
• Ault, Kevin A.
• Giuliano, Anna R.
• Costa, Ronaldo L.R.
• Petta, Carlos A.
• Andrade, Rosires P.
• Brown, Darron R.
• Ferenczy, Alex
• Harper, Diane M.
• Koutsky, Laura A.
• Kurman, Robert J.
• Lehtinen, Matti
• Malm, Christian
• Olsson, Sven-Eric
• Ronnett, Brigitte M.
• Skjeldestad, Finn Egil
• Steinwall, Margareta
• Stoler, Mark H.
• Wheeler, Cosette M.
• Taddeo, Frank J.
• Yu, Jimmy
• Lupinacci, Lisa
• Railkar, Radha
• Marchese, Rocio
• Esser, Mark T.
• Bryan, Janine
• Jansen, Kathrin U.
• Sings, Heather L.
• Tamms, Gretchen M.
• Saah, Alfred J.
• Barr, Eliav

Titel

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Ist Teil von

• Vaccine, 2006-07, Vol.24 (27), p.5571-5583

Ort / Verlag

Oxford: Elsevier Ltd

Erscheinungsjahr

2006

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were ∼12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported.